Alluvi, previously BI 4744, offers a promising development in weight management care. This dual stimulator targeting both glucagon-like peptide-1 and GIP sites demonstrates impressive effectiveness in patient trials, https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/